<DOC>
	<DOC>NCT02589964</DOC>
	<brief_summary>The study will evaluate the effectiveness of probiotic therapy in reducing the incidence of antibiotic associated diarrhea (AAD) and Clostridium difficile associated diarrhea (CDAD) in pneumonia patients.</brief_summary>
	<brief_title>Probiotics in the Reduction of Antibiotic Associated Diarrhea</brief_title>
	<detailed_description>The study will include patients admitted to Good Samariatan Hospital and placed on the pneumonia order set. After obtaining consent, subjects will be randomized to the proboiotic or placebo group. Subjects will be followed for 21 days after starting the study treatment to determine critical outcomes such as incidence of antibiotic-associated diarrhea and C-Diff. Other outcomes include length of stay, healthcare costs, and death.</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics, Antitubercular</mesh_term>
	<criteria>Admitted to Good Samaritan Hospital Placed on pneumonia order set Age 18+ Patient with inadequate coherency to understand consent Active Diarrhea at admission Noncontrolled intestinal disease Documented positive C. difficile infection within the 3 months before enrollment Antibiotic use at hospital admission Immunosuppressive therapy Pregnancy Allergic to ingredients in Florajen3 Allergic to ingredients in placebo Immunocompromised state including: HIV with a low CD4 count Active malignancy receiving chemotherapy Medications including longterm steroids (&gt;2 weeks), and disease modifying biologic agents Acquired immune deficiency Unable to take oral medication Less than 4 doses of probiotic or placebo Taking probiotic in the past 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>probiotics</keyword>
	<keyword>antibiotic associated diarrhea</keyword>
	<keyword>clostridium difficile</keyword>
</DOC>